Experienced in Anomalous Left Coronary Artery from the Pulmonary Artery

Abid R. Assali

39 Jabotinsky St, 
Petah Tiqwa, M, IL 
Experienced in Anomalous Left Coronary Artery from the Pulmonary Artery
39 Jabotinsky St, 
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Abid Assali practices in Petah Tiqwa, Israel. Mr. Assali is rated as an Experienced expert by MediFind in the treatment of Anomalous Left Coronary Artery from the Pulmonary Artery. His top areas of expertise are Aortic Valve Stenosis, Coronary Heart Disease, Heart Attack, Transcatheter Aortic Valve Replacement (TAVR), and Percutaneous Coronary Intervention (PCI).

His clinical research consists of co-authoring 152 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Anomalous Left Coronary Artery from the Pulmonary Artery.

Gender
Male

Locations

39 Jabotinsky St, Petah Tiqwa, M 49100, Israel
Other Locations
6 Weizmann Street, Tel Aviv, TA 62439, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Prospective, Multi-Center, Non-randomized, Single Arm, Open Label, Supplemental Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions
A Prospective, Multi-Center, Non-randomized, Single Arm, Open Label, Supplemental Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions
Enrollment Status: Completed
Publish Date: December 03, 2019
Intervention Type: Device
Study Phase: Not Applicable
FFRangio Accuracy vs. Standard FFR
FFRangio Accuracy vs. Standard FFR
Enrollment Status: Completed
Publish Date: June 25, 2018
Intervention Type: Device
View 2 Less Clinical Trials

152 Total Publications

SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.
SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease.
Journal: Cardiovascular diabetology
Published: June 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Assali's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile